biote (BTMD)
Builds and supports clinician practices offering pellet-based hormone optimization.
$1.31
vs last close−0.01 (−0.76%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46 | 46 | 47 | 49 | 51 | 50 | 49 | 49 | 48 | 46 | 45 | 44 |
| Cost of revenue | 14 | 14 | 13 | 15 | 15 | 14 | 13 | 14 | 14 | 15 | 14 | 31 |
| Gross profit | 31 | 32 | 33 | 34 | 36 | 36 | 36 | 35 | 34 | 32 | 31 | 14 |
| 24 | 26 | 23 | 28 | 24 | 33 | 27 | 24 | 26 | 25 | 28 | 17 | |
| 0 | 26 | 23 | 28 | 24 | 33 | 27 | 24 | 26 | 25 | 28 | 32 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 |
| Other expenses | 24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −15 |
| Operating income | 8 | 6 | 10 | 6 | 12 | 3 | 10 | 11 | 8 | 7 | 3 | −4 |
| 16 | 4 | −14 | −17 | 4 | −4 | 8 | −5 | 0 | −1 | 0 | −4 | |
| Interest expense | 2 | 2 | 2 | 3 | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Other non-operating income | −3 | −4 | 12 | −2 | −7 | 1 | −11 | 2 | −3 | −1 | −2 | 1 |
| Income before tax | 24 | 9 | −3 | −10 | 16 | −1 | 17 | 6 | 8 | 6 | 3 | −7 |
| Income tax expense | 4 | −3 | 2 | 0 | 3 | −5 | 2 | 2 | −1 | 3 | 1 | 0 |
| Net income from continuing operations | 20 | 12 | −6 | −10 | 13 | 3 | 16 | 4 | 9 | 3 | 3 | −7 |
| Net income | 8 | 8 | −4 | −7 | 11 | 4 | 14 | 3 | 8 | 2 | 2 | −7 |
| EPS, basic | $0.25 | $0.12 | −$0.06 | −$0.19 | $0.34 | $0.12 | $0.44 | $0.10 | $0.26 | $0.06 | $0.07 | −$0.23 |
| EPS, diluted | $0.24 | $0.12 | −$0.06 | −$0.19 | $0.33 | $0.10 | $0.37 | $0.10 | $0.22 | $0.06 | $0.06 | −$0.23 |
| Weighted average shares, basic | 30 | 30 | 35 | 33 | 31 | 31 | 31 | 32 | 31 | 31 | 31 | 29 |
| Weighted average shares, diluted | 31 | 30 | 35 | 33 | 32 | 37 | 37 | 37 | 37 | 31 | 36 | 29 |
| EBITDA | 11 | 10 | −1 | 9 | 20 | 3 | 21 | 10 | 12 | 9 | 6 | −4 |
| Depreciation & amortization | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBIT | 10 | 10 | −2 | 8 | 19 | 2 | 20 | 9 | 11 | 8 | 5 | −5 |